Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • emc易倍官网入口Media Resources
    • Media Contacts
    • Subscribe
  • Investors
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • emc易倍官网入口Subscribe
    • Ratings & Bonds
  • Careers
      < Back
    • Careers
    • emc易倍官网入口Careers
    • emc易倍官网入口Working at Ipsen
    • emc易倍官网入口Culture
    • emc易倍官网入口Job Search
  • Contacts
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • emc易倍官网入口Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     emc易倍官网入口 Fran?ais  FR     EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • emc易倍官网入口Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • Canada
    • emc易倍官网入口 United States
    • Mexico
    • emc易倍官网入口 Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • emc易倍官网入口 Germany
    • emc易倍官网入口 France
    • emc易倍官网入口 Nordics
    • Greece
    • Italy
    • emc易倍官网入口 Netherlands
    • Spain
    • emc易倍官网入口 Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • emc易倍官网入口 Slovakia
    • Switzerland
    • Austria
    • emc易倍官网入口 UAE & Gulf
    • emc易倍官网入口 Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • emc易倍官网入口Company
    • Leadership
    • emc易倍官网入口History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • emc易倍官网入口Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • emc易倍官网入口Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • emc易倍官网入口Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • emc易倍官网入口Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • emc易倍官网入口Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • emc易倍官网入口Collaborate with us
  • Stories

emc易倍官网入口

Previous
Next

emc易倍官网入口

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-09-17-Ipsen-Voting-rights

emc易倍官网入口

- 12 January 2021 - 1 mins read

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-09-17-Ipsen-Voting-rights

emc易倍官网入口

Previous
Next
Related stories
01 June 2021 1 mins read

Ipsen announces the launch of an Employee Shareholding Plan
emc易倍官网入口 See more stories

emc易倍官网入口

11 July 2024

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for...
09 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
09 July 2024

Ipsen – June 2024 – Monthly information relative to the...
08 July 2024

Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
02 July 2024

Ipsen expands collaboration and license agreement for development of Cabometyx?...
25 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
18 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
11 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
10 June 2024

Ipsen’s Iqirvo? receives U.S. FDA accelerated approval as a first-in-class...

IPN price

€155.60

 €-3.00 (-1.89%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy
  • LinkedIn
  • Instagram
  • Facebook
  • Youtube

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

What information or content were you unable to find on the Ipsen website?









2026-09-17 20:05:08